Literature DB >> 24277376

Significant associations between X-ray repair cross-complementing group 3 genetic polymorphisms and thyroid cancer risk.

Xiao-Long Yu1, Hu Liu, Bin Wang, Zheng-Ju Fu, Ying Yuan, Sheng-Li Yan, Wen-Juan Zhao, Yan-Gang Wang, Jianming Cai.   

Abstract

Polymorphisms in X-ray cross-complementing group 3 (XRCC3) are proposed to be associated with cancer susceptibility, but previous studies on the associations between XRCC3 polymorphisms and thyroid cancer are controversial. We performed a systemic review and meta-analysis to investigate the associations of XRCC3 polymorphisms with thyroid cancer risk. We used odds ratio (OR) with 95 % confidence interval (95%CI) to assess the associations. For XRCC3 C241T polymorphism, meta-analysis of total eligible studies showed that there was no association between XRCC3 C241T polymorphism and thyroid cancer risk, but subgroup analysis in Caucasians showed that there was a significant association between XRCC3 C241T polymorphism and thyroid cancer risk (T versus C: OR = 1.30, 95%CI 1.05-1.62, P = 0.01; TT versus CC: OR = 1.74, 95%CI 1.13-2.70, P = 0.01; TT versus CC/CT: OR = 1.74, 95%CI 1.16-2.60, P = 0.007). For XRCC3 A17893G polymorphism, meta-analysis of total eligible studies showed that there was an obvious association between XRCC3 A17893G polymorphism and thyroid cancer risk (GG versus AA/AG: OR = 0.57, 95%CI 0.35-0.93, P = 0.02), but subgroup analysis by ethnicity only identify the significant association in Asians. In summary, the meta-analysis suggests that there are significant associations of XRCC3 polymorphisms with thyroid cancer risk. Besides, more studies with large sample sizes are needed to further assess the associations above.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24277376     DOI: 10.1007/s13277-013-1266-1

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  24 in total

1.  Statistical aspects of the analysis of data from retrospective studies of disease.

Authors:  N MANTEL; W HAENSZEL
Journal:  J Natl Cancer Inst       Date:  1959-04       Impact factor: 13.506

2.  Bias in meta-analysis detected by a simple, graphical test.

Authors:  M Egger; G Davey Smith; M Schneider; C Minder
Journal:  BMJ       Date:  1997-09-13

Review 3.  Multikinase inhibitors: a new option for the treatment of thyroid cancer.

Authors:  Matti L Gild; Martyn Bullock; Bruce G Robinson; Roderick Clifton-Bligh
Journal:  Nat Rev Endocrinol       Date:  2011-08-23       Impact factor: 43.330

4.  Radiation dose-response relationships for thyroid nodules and autoimmune thyroid diseases in Hiroshima and Nagasaki atomic bomb survivors 55-58 years after radiation exposure.

Authors:  Misa Imaizumi; Toshiro Usa; Tan Tominaga; Kazuo Neriishi; Masazumi Akahoshi; Eiji Nakashima; Kiyoto Ashizawa; Ayumi Hida; Midori Soda; Saeko Fujiwara; Michiko Yamada; Eri Ejima; Naokata Yokoyama; Masamichi Okubo; Keizo Sugino; Gen Suzuki; Renju Maeda; Shigenobu Nagataki; Katsumi Eguchi
Journal:  JAMA       Date:  2006-03-01       Impact factor: 56.272

Review 5.  Molecular genetics and diagnosis of thyroid cancer.

Authors:  Yuri E Nikiforov; Marina N Nikiforova
Journal:  Nat Rev Endocrinol       Date:  2011-08-30       Impact factor: 43.330

Review 6.  Chromatin remodeling at DNA double-strand breaks.

Authors:  Brendan D Price; Alan D D'Andrea
Journal:  Cell       Date:  2013-03-14       Impact factor: 41.582

7.  Polymorphisms of DNA damage response genes in radiation-related and sporadic papillary thyroid carcinoma.

Authors:  Natallia M Akulevich; Vladimir A Saenko; Tatiana I Rogounovitch; Valentina M Drozd; Eugeny F Lushnikov; Victor K Ivanov; Norisato Mitsutake; Ryo Kominami; Shunichi Yamashita
Journal:  Endocr Relat Cancer       Date:  2009-03-13       Impact factor: 5.678

Review 8.  Histone modifications and DNA double-strand break repair after exposure to ionizing radiations.

Authors:  Clayton R Hunt; Deepti Ramnarain; Nobuo Horikoshi; Puneeth Iyengar; Raj K Pandita; Jerry W Shay; Tej K Pandita
Journal:  Radiat Res       Date:  2013-02-01       Impact factor: 2.841

Review 9.  The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance.

Authors:  Peter Bouwman; Jos Jonkers
Journal:  Nat Rev Cancer       Date:  2012-09       Impact factor: 60.716

10.  Common variants on 9q22.33 and 14q13.3 predispose to thyroid cancer in European populations.

Authors:  Julius Gudmundsson; Patrick Sulem; Daniel F Gudbjartsson; Jon G Jonasson; Asgeir Sigurdsson; Jon T Bergthorsson; Huiling He; Thorarinn Blondal; Frank Geller; Margret Jakobsdottir; Droplaug N Magnusdottir; Sigurborg Matthiasdottir; Simon N Stacey; Oskar B Skarphedinsson; Hafdis Helgadottir; Wei Li; Rebecca Nagy; Esperanza Aguillo; Eduardo Faure; Enrique Prats; Berta Saez; Mariano Martinez; Gudmundur I Eyjolfsson; Unnur S Bjornsdottir; Hilma Holm; Kristleifur Kristjansson; Michael L Frigge; Hoskuldur Kristvinsson; Jeffrey R Gulcher; Thorvaldur Jonsson; Thorunn Rafnar; Hannes Hjartarsson; Jose I Mayordomo; Albert de la Chapelle; Jon Hrafnkelsson; Unnur Thorsteinsdottir; Augustine Kong; Kari Stefansson
Journal:  Nat Genet       Date:  2009-02-06       Impact factor: 38.330

View more
  4 in total

1.  Association between XRCC1 and XRCC3 gene polymorphisms and risk of thyroid cancer.

Authors:  Xufu Wang; Kunpeng Zhang; Xinfeng Liu; Bin Liu; Zhenguang Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

Review 2.  Association of XRCC3 gene rs861539 polymorphism with gastric cancer risk: evidence from a case-control study and a meta-analysis.

Authors:  Shidan Cheng; Liying Wang; Lei Wang; Zhengting Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

3.  Association Between X-Ray Cross-complementing Group 3 (XRCC3) Thr241Met Polymorphism and Risk of Thyroid Cancer: A Meta-Analysis.

Authors:  Wenying Lu; Guiqi Wu; Bo Zhang
Journal:  Med Sci Monit       Date:  2015-12-21

4.  The significance of Exo1 K589E polymorphism on cancer susceptibility: evidence based on a meta-analysis.

Authors:  Fujiao Duan; Chunhua Song; Liping Dai; Shuli Cui; Xiaoqin Zhang; Xia Zhao
Journal:  PLoS One       Date:  2014-05-08       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.